Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection.

Abouelasrar Salama S, Lavie M, De Buck M, Van Damme J, Struyf S.

Cytokine Growth Factor Rev. 2019 Oct 28. pii: S1359-6101(19)30105-4. doi: 10.1016/j.cytogfr.2019.10.006. [Epub ahead of print] Review.

PMID:
31718982
2.

Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities.

Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S.

Ocul Immunol Inflamm. 2019 Jun 4:1-10. doi: 10.1080/09273948.2019.1604974. [Epub ahead of print]

PMID:
31161935
3.

Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction.

Moens L, Gouwy M, Bosch B, Pastukhov O, Nieto-Patlàn A, Siler U, Bucciol G, Mekahli D, Vermeulen F, Desmet L, Maebe S, Flipts H, Corveleyn A, Moshous D, Philippet P, Tangye SG, Boisson B, Casanova JL, Florkin B, Struyf S, Reichenbach J, Bustamante J, Notarangelo LD, Meyts I.

J Clin Immunol. 2019 Apr;39(3):298-308. doi: 10.1007/s10875-019-00603-w. Epub 2019 Mar 5.

4.

Expression of interleukin (IL)-10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of IL-19 in human leucocyte antigen-B27-associated uveitis.

Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S.

Acta Ophthalmol. 2019 Aug;97(5):e780-e784. doi: 10.1111/aos.14039. Epub 2019 Feb 13.

PMID:
30761764
5.

Pathological roles of the homeostatic chemokine CXCL12.

Janssens R, Struyf S, Proost P.

Cytokine Growth Factor Rev. 2018 Dec;44:51-68. doi: 10.1016/j.cytogfr.2018.10.004. Epub 2018 Oct 23. Review.

PMID:
30396776
6.

Chemokine-Induced Macrophage Polarization in Inflammatory Conditions.

Ruytinx P, Proost P, Van Damme J, Struyf S.

Front Immunol. 2018 Sep 7;9:1930. doi: 10.3389/fimmu.2018.01930. eCollection 2018. Review.

7.

The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis.

Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S.

Acta Ophthalmol. 2019 Feb;97(1):e122-e128. doi: 10.1111/aos.13835. Epub 2018 Sep 21.

PMID:
30242977
8.

Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity.

Janssens R, Boff D, Ruytinx P, Mortier A, Vanheule V, Larsen O, Daugvilaite V, Rosenkilde MM, Noppen S, Liekens S, Schols D, De Meester I, Opdenakker G, Struyf S, Teixeira MM, Amaral FA, Proost P.

Front Immunol. 2018 Aug 28;9:1933. doi: 10.3389/fimmu.2018.01933. eCollection 2018.

9.

Anti-inflammatory effects of the GAG-binding CXCL9(74-103) peptide in dinitrofluorobenzene-induced contact hypersensitivity in mice.

Vanheule V, Crijns H, Poosti F, Ruytinx P, Berghmans N, Gerlza T, Ronsse I, Pörtner N, Matthys P, Kungl AJ, Opdenakker G, Struyf S, Proost P.

Clin Exp Allergy. 2018 Oct;48(10):1333-1344. doi: 10.1111/cea.13227. Epub 2018 Aug 14.

PMID:
29978510
10.

Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.

Gouwy M, De Buck M, Abouelasrar Salama S, Vandooren J, Knoops S, Pörtner N, Vanbrabant L, Berghmans N, Opdenakker G, Proost P, Van Damme J, Struyf S.

Front Immunol. 2018 Jun 4;9:1081. doi: 10.3389/fimmu.2018.01081. eCollection 2018.

11.

CXCL4 and CXCL4L1 in cancer.

Ruytinx P, Proost P, Struyf S.

Cytokine. 2018 Sep;109:65-71. doi: 10.1016/j.cyto.2018.02.022. Review.

PMID:
29903575
12.

How post-translational modifications influence the biological activity of chemokines.

Vanheule V, Metzemaekers M, Janssens R, Struyf S, Proost P.

Cytokine. 2018 Sep;109:29-51. doi: 10.1016/j.cyto.2018.02.026. Review.

PMID:
29903573
13.

The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round.

De Buck M, Gouwy M, Struyf S, Opdenakker G, Van Damme J.

Immunol Lett. 2019 Jan;205:1-8. doi: 10.1016/j.imlet.2018.06.001. Epub 2018 Jun 2. Review.

PMID:
29870759
14.

Differential CXC and CX3C Chemokine Expression Profiles in Aqueous Humor of Patients With Specific Endogenous Uveitic Entities.

El-Asrar AMA, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S.

Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2222-2228. doi: 10.1167/iovs.17-23225.

PMID:
29715366
15.

Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands.

Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P.

Front Immunol. 2018 Jan 15;8:1970. doi: 10.3389/fimmu.2017.01970. eCollection 2017. Review.

16.

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.

De Buck M, Gouwy M, Berghmans N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Blood. 2018 Jan 25;131(4):439-449. doi: 10.1182/blood-2017-06-788554..

PMID:
29371208
17.

Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.

Dierckx de Casterlé I, Fevery S, Rutgeerts O, Poosti F, Struyf S, Lenaerts C, Waer M, Billiau AD, Sprangers B.

Cancer Immunol Immunother. 2018 Apr;67(4):589-603. doi: 10.1007/s00262-017-2114-8. Epub 2018 Jan 3.

PMID:
29299660
18.

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.

De Buck M, Gouwy M, Berghmans N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Blood. 2017 Dec 4. pii: blood-2017-06-788554. doi: 10.1182/blood-2017-06-788554. [Epub ahead of print]

PMID:
29203586
19.

Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Cockx M, Gouwy M, Van Damme J, Struyf S.

Cell Mol Immunol. 2018 Apr;15(4):312-323. doi: 10.1038/cmi.2017.118. Epub 2017 Nov 27. Review.

20.

Monocytes from patients with Primary Ciliary Dyskinesia show enhanced inflammatory properties and produce higher levels of pro-inflammatory cytokines.

Cockx M, Gouwy M, Ruytinx P, Lodewijckx I, Van Hout A, Knoops S, Pörtner N, Ronsse I, Vanbrabant L, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Sci Rep. 2017 Nov 7;7(1):14657. doi: 10.1038/s41598-017-15027-y.

21.

The unique structural and functional features of CXCL12.

Janssens R, Struyf S, Proost P.

Cell Mol Immunol. 2018 Apr;15(4):299-311. doi: 10.1038/cmi.2017.107. Epub 2017 Oct 30. Review.

22.

Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands.

Cockx M, Gouwy M, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Front Immunol. 2017 Sep 22;8:1126. doi: 10.3389/fimmu.2017.01126. eCollection 2017.

23.

Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.

Ruytinx P, Janssens R, Berghmans N, Gouwy M, Ronsse I, Liekens S, Proost P, Van Damme J, Struyf S.

Biochem Pharmacol. 2017 Dec 1;145:123-131. doi: 10.1016/j.bcp.2017.08.020. Epub 2017 Aug 30.

PMID:
28859966
24.

Chemokine isoforms and processing in inflammation and immunity.

Proost P, Struyf S, Van Damme J, Fiten P, Ugarte-Berzal E, Opdenakker G.

J Autoimmun. 2017 Dec;85:45-57. doi: 10.1016/j.jaut.2017.06.009. Epub 2017 Jul 3. Review.

PMID:
28684129
25.

Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.

Abu El-Asrar AM, Struyf S, Mohammad G, Gouwy M, Rytinx P, Siddiquei MM, Hernández C, Alam K, Mousa A, De Hertogh G, Opdenakker G, Simó R.

Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3189-3201. doi: 10.1167/iovs.16-20993.

PMID:
28654984
26.

Tumor angiogenesis revisited: Regulators and clinical implications.

Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S.

Med Res Rev. 2017 Nov;37(6):1231-1274. doi: 10.1002/med.21452. Epub 2017 Jun 23. Review.

PMID:
28643862
27.

CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions.

Vanheule V, Boff D, Mortier A, Janssens R, Petri B, Kolaczkowska E, Kubes P, Berghmans N, Struyf S, Kungl AJ, Teixeira MM, Amaral FA, Proost P.

Front Immunol. 2017 May 10;8:530. doi: 10.3389/fimmu.2017.00530. eCollection 2017.

28.

Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.

Janssens R, Mortier A, Boff D, Ruytinx P, Gouwy M, Vantilt B, Larsen O, Daugvilaite V, Rosenkilde MM, Parmentier M, Noppen S, Liekens S, Van Damme J, Struyf S, Teixeira MM, Amaral FA, Proost P.

Biochem Pharmacol. 2017 May 15;132:92-101. doi: 10.1016/j.bcp.2017.03.009. Epub 2017 Mar 18.

PMID:
28322746
29.

Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.

Dinsart C, Pervolaraki K, Stroh-Dege A, Lavie M, Ronsse I, Rommelaere J, Van Damme J, Van Raemdonck K, Struyf S.

Hum Gene Ther. 2017 Mar;28(3):295-306. doi: 10.1089/hum.2016.108. Epub 2016 Dec 29.

PMID:
28042949
30.

CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.

Gouwy M, Ruytinx P, Radice E, Claudi F, Van Raemdonck K, Bonecchi R, Locati M, Struyf S.

PLoS One. 2016 Nov 9;11(11):e0166006. doi: 10.1371/journal.pone.0166006. eCollection 2016.

31.

The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 Are Novel Biomarkers of Specific Endogenous Uveitic Entities.

Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Mousa A, Opdenakker G, Van Damme J, Struyf S.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4606-13. doi: 10.1167/iovs.16-19758.

PMID:
27603722
32.

Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo.

Janssens R, Mortier A, Boff D, Vanheule V, Gouwy M, Franck C, Larsen O, Rosenkilde MM, Van Damme J, Amaral FA, Teixeira MM, Struyf S, Proost P.

Oncotarget. 2016 Sep 20;7(38):62439-62459. doi: 10.18632/oncotarget.11516.

33.

Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.

De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S, Van Damme J.

Curr Med Chem. 2016;23(17):1725-55. Review.

34.

Transforming Growth Factor Beta Switch in Aqueous Humor of Patients With Fuchs' Endothelial Corneal Dystrophy.

De Roo AK, Struyf S, Foets B, van den Oord JJ.

Invest Ophthalmol Vis Sci. 2016 Feb;57(2):771-2. doi: 10.1167/iovs.15-18768. No abstract available.

PMID:
26927570
35.

The cytokine-serum amyloid A-chemokine network.

De Buck M, Gouwy M, Wang JM, Van Snick J, Proost P, Struyf S, Van Damme J.

Cytokine Growth Factor Rev. 2016 Aug;30:55-69. doi: 10.1016/j.cytogfr.2015.12.010. Epub 2015 Dec 28. Review.

PMID:
26794452
36.

CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology.

Mortier A, Gouwy M, Van Damme J, Proost P, Struyf S.

J Leukoc Biol. 2016 Jun;99(6):955-69. doi: 10.1189/jlb.3MR0915-401R. Epub 2016 Jan 7. Review.

PMID:
26744452
37.

Serum amyloid A1α induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils.

De Buck M, Berghmans N, Pörtner N, Vanbrabant L, Cockx M, Struyf S, Opdenakker G, Proost P, Van Damme J, Gouwy M.

J Leukoc Biol. 2015 Dec;98(6):1049-60. doi: 10.1189/jlb.3A0315-085R. Epub 2015 Aug 21.

PMID:
26297794
38.

The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood-Retinal Barrier Breakdown.

Abu El-Asrar AM, Mohammad G, Nawaz MI, Abdelsaid M, Siddiquei MM, Alam K, Van den Eynde K, De Hertogh G, Opdenakker G, Al-Shabrawey M, Van Damme J, Struyf S.

Invest Ophthalmol Vis Sci. 2015 Feb 24;56(3):1956-64. doi: 10.1167/iovs.14-16144.

39.

Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT).

Abu El-Asrar AM, De Hertogh G, van den Eynde K, Alam K, Van Raemdonck K, Opdenakker G, Van Damme J, Geboes K, Struyf S.

Exp Eye Res. 2015 Mar;132:179-89. doi: 10.1016/j.exer.2015.01.023. Epub 2015 Jan 28.

PMID:
25637870
40.

CXCR3 ligands in disease and therapy.

Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S.

Cytokine Growth Factor Rev. 2015 Jun;26(3):311-27. doi: 10.1016/j.cytogfr.2014.11.009. Epub 2014 Nov 22. Review.

PMID:
25498524
41.

Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.

Van Raemdonck K, Berghmans N, Vanheule V, Bugatti A, Proost P, Opdenakker G, Presta M, Van Damme J, Struyf S.

Oncotarget. 2014 Nov 15;5(21):10916-33.

42.

Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines.

Gouwy M, De Buck M, Pörtner N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Eur J Immunol. 2015 Jan;45(1):101-12. doi: 10.1002/eji.201444818. Epub 2014 Dec 1.

43.

CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.

Van Raemdonck K, Gouwy M, Lepers SA, Van Damme J, Struyf S.

Angiogenesis. 2014 Jul;17(3):631-40. doi: 10.1007/s10456-014-9417-6. Epub 2014 Jan 28.

PMID:
24469069
44.

Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells.

Gouwy M, Struyf S, Leutenez L, Pörtner N, Sozzani S, Van Damme J.

Immunobiology. 2014 Mar;219(3):218-29. doi: 10.1016/j.imbio.2013.10.004. Epub 2013 Oct 14.

PMID:
24268109
45.

Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.

Lavie M, Struyf S, Stroh-Dege A, Rommelaere J, Van Damme J, Dinsart C.

Virology. 2013 Dec;447(1-2):221-32. doi: 10.1016/j.virol.2013.09.019. Epub 2013 Oct 4.

46.

CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model.

Besnard AG, Struyf S, Guabiraba R, Fauconnier L, Rouxel N, Proost P, Uyttenhove C, Van Snick J, Couillin I, Ryffel B.

J Leukoc Biol. 2013 Dec;94(6):1317-23. doi: 10.1189/jlb.0313140. Epub 2013 Aug 23.

PMID:
23975892
47.

Neurotrophins and neurotrophin receptors in proliferative diabetic retinopathy.

Abu El-Asrar AM, Mohammad G, De Hertogh G, Nawaz MI, Van Den Eynde K, Siddiquei MM, Struyf S, Opdenakker G, Geboes K.

PLoS One. 2013 Jun 7;8(6):e65472. doi: 10.1371/journal.pone.0065472. Print 2013.

48.

Pathogenesis of malaria-associated acute respiratory distress syndrome.

Van den Steen PE, Deroost K, Deckers J, Van Herck E, Struyf S, Opdenakker G.

Trends Parasitol. 2013 Jul;29(7):346-58. doi: 10.1016/j.pt.2013.04.006. Epub 2013 Jun 3. Review.

PMID:
23742967
49.

Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.

Nawaz MI, Van Raemdonck K, Mohammad G, Kangave D, Van Damme J, Abu El-Asrar AM, Struyf S.

Exp Eye Res. 2013 Apr;109:67-76. doi: 10.1016/j.exer.2013.01.008. Epub 2013 Jan 22.

PMID:
23352833
50.

Identification and characterization of MIP-1α/CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant.

De Buck M, Gouwy M, Proost P, Struyf S, Van Damme J.

Biochem Pharmacol. 2013 Mar 15;85(6):789-97. doi: 10.1016/j.bcp.2012.11.027. Epub 2012 Dec 7.

PMID:
23228695

Supplemental Content

Loading ...
Support Center